Hyperprolactinaemia: diagnosis and management – GP online
Posted: February 16, 2017 at 1:51 am
Raised prolactin levels and their management, including clinical presentations, recent research on dopamine agonists and when surgery may be indicated.
Coloured CR scan showing a side view of a tumour (orange) of the pituitary gland (Picture: Science Photo Library)
Hyperprolactinaemia is a raised level of prolactin in the blood. This hormone stimulates breast epithelial cell proliferation and induces milk production. However, excessive production of prolactin can lead to infertility and gonadal dysfunction.1
Prolactin suppresses gonadotrophin-releasing hormone (GnRH), resulting in suppression of ovulation in females and reduced testosterone levels and hypogonadism in males.
Prolactin levels are normally high during pregnancy and lactation. Levels also increase after meals, after exercise and during stress, as well as during sleep.
Abnormally high levels of prolactin may be caused by a prolactin-secreting pituitary tumour (prolactinoma), or by a non-secreting pituitary tumour that prevents dopamine (a prolactin release-inhibiting hormone) from reaching normal prolactin-producing cells.
Common and rarer causes
Prolactinomas are the most common cause of hyperprolactinaemia, although it has many different causes. They are benign tumours that account for 40% of pituitary tumours and are the most common type of pituitary adenomas. More than 90% are intrasellar microprolactinomas (<10mm) that seldom increase in size.
Primary hypothyroidism may lead to hyperprolactinaemia as a consequence of increased synthesis of thyrotropin-releasing hormone, which stimulates prolactin production.
Severe liver disease and chronic renal failure can also be causes. Head injuries, brain surgery and cranial radiotherapy can also cause hyperprolactinaemia.
Drugs
The commonest medications to cause hyperprolactinaemia are antipsychotic drugs. Antidepressants, opiates, verapamil and oestrogens can also lead to hyperprolactinaemia.
Mildly increased prolactin levels (400-600mu/L) may be physiological and asymptomatic but higher levels are usually pathological. Very elevated levels (above 5,000mu/L) usually imply a prolactin-secreting pituitary tumour. Most patients with a prolactinoma are women.
The clinical presentation in women is more obvious and so occurs earlier than in men. Women present most commonly with galactorrhoea (up to 90% of cases), menstrual disturbance, reduced fertility and libido. Men present with galactorrhoea (10-20% of men), loss of libido, erectile dysfunction and occasionally, reduced fertility and gynaecomastia.
In both sexes, a macroadenoma (>10 mm in diameter) can cause mass effects, which may result in visual-field defects or headache.
In both sexes, long-standing hyperprolactinaemia can lead to low bone mineral density with an increased risk of developing osteoporosis.
A single measurement of prolactin level is usually adequate to diagnose hyperprolactinaemia. However, when the result is borderline, the test should be repeated. The pain/stress of venepuncture can actually elevate prolactin levels. Obviously, pregnancy must be excluded, if relevant. Renal and thyroid function tests should also be performed.
When other causes of hyperprolactinaemia have been excluded, the diagnosis of a prolactinoma is usually confirmed by a pituitary MRI scan.
Patients with macroadenomas that extend beyond the sella should undergo testing to exclude visual field defects, and also dynamic testing of the anterior pituitary function to exclude hypopituitarism.
Treatment of hyperprolactinaemia will vary according to the cause - for example, a drug review may be required where it is drug-related. The aim of treatment is to improve symptoms and avoid the long-term effects of oestrogen deficiency in women or testosterone deficiency in men.
Dopamine agonists suppress prolactin in most patients, normalise gonadal function and stop galactorrhoea. In patients with prolactinomas, they reduce the size of the tumour.2
Cabergoline and bromocriptine are both ergot-based dopamine receptor agonists. Cabergoline is the first-line treatment for prolactinomas as it has greater efficacy in suppressing prolactin secretion. It is better tolerated and has a more convenient dosing regimen when compared with bromocriptine.
The MHRA issued a warning in the past about the safety of dopamine agonists for treating hyperprolactinaemia, due to concerns about an association with chronic pleuropulmonary, pericardial and retroperitoneal fibrosis, and particularly fibrotic valvular heart disease.3
However, recent studies have not shown a clinically significant association between the use of ergot-derived dopamine agonist drugs for the treatment of hyperprolactinaemia and valvulopathy.4,5
In some patients with microprolactinomas, withdrawal of treatment can be tried after three years, as microprolactinomas can spontaneously resolve, especially after the menopause or pregnancy. Transsphenoidal surgery is an option in infertile patients who cannot tolerate or are resistant to dopamine agonists. It may also be performed if a macroadenoma does not shrink with drug treatment.
Definitive treatment depends on the size of the tumour and the patient's wishes (including future fertility).
Over 90% of microadenomas remain stable or gradually reduce their secretion of prolactin. One third of patients with idiopathic hyperprolactinaemia improve without treatment. This is more common in women around their menopause.
However, recurrence rates of hyperprolactinaemia are as high as 80 per cent, and therefore the majority of patients require long-term medical treatment.
This is an updated version of an article that was first published in September 2009.
Useful website: Pituitary Foundation -www.pituitary.org.uk
See the rest here:
Hyperprolactinaemia: diagnosis and management - GP online
- Correction of In-Patient Severe Hypernatremia in an 81-Year-Old Female With Hypopituitarism - Cureus - January 3rd, 2024
- Hypopituitarism: Symptoms, causes, and treatment - Medical News Today - December 25th, 2023
- Hypopituitarism - Hormonal and Metabolic Disorders - Merck Manuals ... - November 27th, 2023
- Diagnosis and Treatment of Hypopituitarism - PMC - National Center for ... - April 18th, 2023
- Hypopituitarism - StatPearls - NCBI Bookshelf - February 10th, 2023
- Panhypopituitarism: What It Is, Symptoms & Treatment - Cleveland Clinic - February 10th, 2023
- Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society ... - November 1st, 2022
- 31 days of horror movies: Orphan: First Kill is a reminder to have fun with movies - 1428 Elm - October 8th, 2022
- New to Streaming: Ken Jacobs, The Legend of Molly Johnson, Spin Me Round, The Princess & More - The Film Stage - August 20th, 2022
- Nonalcoholic Fatty Liver Disease and Hypothyroidism: What You Need to Know - Cureus - August 20th, 2022
- Global Metabolic Partnering Report 2022: Deal Trends, Players and Financials Analysis of 1100+ Deals Signed Since 2015 - ResearchAndMarkets.com -... - August 20th, 2022
- A Case of Undiagnosed Functional Gonadotroph Adenoma Leading to Ovarian Hyperstimulation Syndrome - Cureus - June 28th, 2022
- Hypopituitarism: Symptoms, Treatment & Diagnosis - May 11th, 2022
- Polyendocrine gland injury induced by an immunosuppressant | DMSO - Dove Medical Press - April 28th, 2022
- Pfizer and Biohaven's VYDURA Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of... - April 28th, 2022
- COVID-19 and hypopituitarism - DocWire News - August 16th, 2021
- Orphan: First Kill Has a Surprise Twist That Could Rival the Original's Shocking Ending - MovieWeb - May 26th, 2021
- Merck (MRK) Granted Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) in Combination with Chemotherapy - StreetInsider.com - May 26th, 2021
- Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival... - May 26th, 2021
- Merck Receives Positive EU CHMP Opinion for KEYTRUDA in Combination With Chemotherapy as First-Line Treatment for Certain Patients With Esophageal... - May 26th, 2021
- Sheehan's syndrome - Symptoms and causes - Mayo Clinic - February 19th, 2021
- atrophy | Definition, Types, & Effects | Britannica - February 19th, 2021
- Hormone Replacement in Hypopituitarism Guideline Resources ... - February 14th, 2021
- World Alopecia Market Segmentation & Impact Analysis, by Gender, Application and Region - Featuring Profiles of Key Players Cipla Inc, Johnson AG,... - December 30th, 2020
- Global Alopecia Market is Forecast to Deliver a CAGR of 5.1% Between 2019 and 2027 - GlobeNewswire - December 14th, 2020
- Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic... - November 13th, 2020
- Alopecia Market Analysis, COVID-19 Impact,Outlook, Opportunities, Size, Share Forecast and Supply Demand 2021-2027|Trusted Business Insights -... - November 10th, 2020
- Male Hypogonadism Market Projected to be Resilient During 2025 - The Market Feed - November 10th, 2020
- Alopecia Market Analysis, COVID-19 Impact,Outlook, Opportunities, Size, Share Forecast and Supply Demand 2021-2027|Trusted Business Insights - KYT24 - November 8th, 2020
- U.S. Food and Drug Administration Accepts for Priority Review Applications for OPDIVO (nivolumab) in Combination with CABOMETYX (cabozantinib) in... - October 23rd, 2020
- Man scared to return home after being stabbed and beaten by intruders in the middle of the night - Yorkshire Live - September 26th, 2020
- Disabled Sheffield man reveals horrific injuries after being stabbed in his own home - The Star - September 22nd, 2020
- BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine - PRNewswire - September 22nd, 2020
- Kristine Barnett: Indiana mum who abandoned 'adult' daughter who tried to kill her cleared of neglect charges - MEAWW - August 19th, 2020
- Global Alopecia Market was valued at approximately USD 2.40 billion in 2019, and is expected to generate revenue of around USD 4.45 billion by end of... - August 11th, 2020
- 20 Of The Most Shocking Plot Twists In Movies That We Never Predicted - ScoopWhoop - August 11th, 2020
- Global Alopecia Market 2020 | Analyzing The COVID-19 Impact Followed By Restraints, Opportunities And Projected Developments - Bulletin Line - August 2nd, 2020
- Diagnosis and Management of Pituitary Incidentaloma - Endocrinology Advisor - June 18th, 2020
- Male Hypogonadism Market Future Aspect Analysis and Current Trends by 2017 to 2025 - 3rd Watch News - May 21st, 2020
- Breakthrough Innovation in Cancer Care From EMD Serono Pipeline to Be Presented at ASCO 2020 - PRNewswire - May 18th, 2020
- Breakthrough Innovation in Cancer Care From EMD Serono Pipeline to Be Presented at ASCO 2020 - WFMZ Allentown - May 16th, 2020
- Hypopituitarism | Endocrine Society - April 13th, 2020
- Certain Types of Steroids Could Increase the Risk of Coronavirus - Myhealthyclick - April 13th, 2020
- EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO for First-Line Maintenance Treatment of... - April 10th, 2020
- Corticosteroids With COVID-19 in Asthma, Allergies, and Arthritis Patients - MedicineNet - April 9th, 2020
- How the Sunflowers Children's Action Group has brought joy to poorly youngsters in lockdown - Grimsby Live - April 9th, 2020
- Patients on Steroids With COVID-19 Might Need Rescue Steroids - Medscape - April 6th, 2020
- Patients taking steroids with COVID-19 may need rescue steroids. - NewsDio - April 6th, 2020
- EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study - P&T Community - March 18th, 2020
- Is dwarf boy Quaden Bayles 18-year-old or just 9? Internet is divided and debate continues - International Business Times, Singapore Edition - February 28th, 2020
- 'Orphan' Prequel to Tell the Origins of 'Esther' - Bloody Disgusting - February 20th, 2020
- Acromegaly Treatment Industry 2020 Global Market Size, Demand, Growth Prospects, Key Insights, Top Companies and Forecast till 2025 - Instant Tech... - February 18th, 2020
- The motive within the serve of this man's suffering became once hiding in undeniable look - Invest Records - January 28th, 2020
- Male Hypogonadism Market Analytical Overview and Growth Opportunities by 2025 - Fusion Science Academy - January 17th, 2020
- Rare Skeleton Points to Compassion, Care, and Tragedy in Prehistoric China - Gizmodo - December 21st, 2019
- Acromegaly Treatment Industry 2019 Global Market Size, Demand, Growth Prospects, Key Insights, Top Companies and Forecast till 2025 - Market Research... - December 20th, 2019
- 5,000-Year-Old Human Found with 'Extremely Rare' Form of Dwarfism - Livescience.com - December 17th, 2019
- How Hypopituitarism is Treated | Learn More About ... - December 11th, 2019
- Acromegaly Treatment Industry 2019 Global Market Size, Demand, Growth Prospects, Key Insights, Top Companies and Forecast till 2025 - VaporBlash - December 5th, 2019
- Alopecia Market Outlook and Opportunities in Grooming Regions with Forecast to 2027 | CAPILLUS, Sun Pharmaceutical Industries, Cipla, Merck and Co,... - November 24th, 2019
- Look inside the old Natwest in Prescot after its total transformation - Liverpool Echo - November 2nd, 2019
- PRACTICALLY ACTIVE: Love your liver and it will love you back - Arkansas Democrat-Gazette - October 9th, 2019
- Male Hypogonadism Market Growth Opportunities and Dynamic Business by 2025 - NewsStoner - September 27th, 2019
- What causes prolonged menstrual bleeding? - The New Times - September 24th, 2019
- CHMP Adopts Positive Opinion for BAVENCIO (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma -... - September 24th, 2019
- Pfizer Presents Scientific Advancements in Cancer Care at the ESMO Congress 2019 Highlighting Expanded Portfolio - Yahoo Finance - September 24th, 2019
- Acute Hypopituitarism: Overview, Diagnostic Considerations ... - May 29th, 2019
- Hypopituitarism | Endocrinology | Dartmouth-Hitchcock - May 2nd, 2019
- Hypopituitarism | Johns Hopkins Medicine - April 11th, 2019
- Hypopituitarism Symptoms & Causes | Boston Children's Hospital - March 6th, 2019
- Endocrine Diseases in Pregnancy | GLOWM - February 18th, 2019
- Non-Functioning Tumors (Endocrine-Inactive Tumors ... - January 29th, 2019
- Steroid Replacement Doses for Hypopituitary Patients ... - January 24th, 2019
- Hypopituitarism | UCLA Health - October 7th, 2018
- Hypopituitarism Disease Reference Guide - Drugs.com - October 3rd, 2018
- Hypopituitarism Treatment & Causes | Lurie Children's - October 3rd, 2018
- Hypopituitarism | You and Your Hormones from the Society for ... - August 23rd, 2018
- Panhypopituitarism: Practice Essentials, Pathophysiology ... - August 23rd, 2018
- Hypopituitarism | Lifespan - August 23rd, 2018
- OMIM Entry - # 146510 - PALLISTER-HALL SYNDROME; PHS - July 26th, 2018